Advancing Treatment of Disease with Innovative protein therapeutics and Technologies

Advancing therapeutics against anemia

Anemia is a condition resulting from low levels of red blood cells or hemoglobin, the body’s main oxygen-carrying components. It is a common side effect of chemotherapy, which is used to treat a variety of cancers. In the US alone, 13.4 million people were diagnosed with cancer in 20111, and about 5 in 10 who received chemotherapy developed anemia, depending on the type of cancer2.

Up until the 1990s blood transfusions were the mainstay of treatment of anemia3. Subsequently, erythropoietin-stimulating agents, such as epoetin alfa and darbepoetin alfa, became the main treatment option for some types of chemotherapy-induced anemia. However, there are serious safety concerns with this class of drugs which have led to a blackbox warning for these products4.

Scientists at Therapure Innovations have discovered a novel pathway (distinct from that of the erythropoietin pathway) involved in the activation of red blood cell precursors to help boost red blood cell production. We have developed a therapeutic monoclonal antibody that utilizes this pathway, which has advanced to phase 1 clinical trials for the treatment of anemia resulting from cancer chemotherapy.


  1. Accessed on March 2015.
  2. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer (Review). Cochrane Database Syst Rev 2012 Dec 12;12:CD003407.
  3. Henry DH. The evolving role of epoetin alfa in cancer therapy. The Oncologist 2004;9:97-107.
  4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cancer- and chemotherapy-induced anemia. Version 2.2014. Accessed August, 2013.

To learn more about our areas of research, platform technologies and pipeline products, or to explore opportunities to partner and/or collaborate with us to improve existing therapeutics, please contact us at